Anglo Asian Mining Share Discussion Threads

[pogue] 15/5/2020 08:24

AVCT do this on news it rises, then falls low around late morning then a rise again. Traders getting out and longer term holders and slow risers buy in. I may top up again today, that will be 3 days in a row, to cover the weekend investors reading up or any news in papers or on BBC.
Now I have written it off course the exact opposite will occur lol

[wanobi] 15/5/2020 08:18

AVCT - yes, a lot of profit takers today Bumpa, understandable :-) Cheers Wan :-)

[bumpa33] 15/5/2020 08:15

Traded AVCT but had to be fast, someone’s using the spike to offload. May settle down later.

Edit: picked up a few more EVG

[fozzie] 15/5/2020 08:09

Yes we have all had ample opportunity to buy in avct. I hold ODX and ORPH, my rationale that they are both solid companies with a future not dependant on C19. Am looking across at avct this morning with very green eyes, good luck to them though, well played.

[callmebwana] 15/5/2020 08:06

Good morning all.

Wan the man from Dell-Monte,he says
Yesssss. Great news from AVCTA.
GLA.

[mad foetus] 15/5/2020 08:06

And they're off, and it's a strong start across the board, with miners moving strongly ahead and gold being the cream of the crop, but where's AAZ. Have they forgotten to open the trap again?

[pogue] 15/5/2020 08:03

MF
its CV19 bingo cover the bases is what I have learnt in this market you don't know who is going to fly on any given day. Currently holding 7 in varying amounts depending on what I think is best bets. I have held more though.

[2sporrans] 15/5/2020 07:59

Aus. big gold miners typically up 4 or 5% today.

Maybe the enthusiasm will extend here.

[wanobi] 15/5/2020 07:57

well done cmb,,,, you held, full size position, 'cool as a cucumber' and you will now be very richly rewarded for your strategy,,, well done Sir, I salute you (again) :-),,,,, Cheers Wan :-)

[onedayrodders] 15/5/2020 07:57

Nice brasso... I was buying 1.5 ounce silver maples for £12 in 2017. I've seen thise very same edition coins are now being sold around £34

[gold finger 1] 15/5/2020 07:55

I see Serabi (SRB)have just rns their results for the three month period ended 31 March 2020. They are not that good at all. Be interesting to see how the market reacts to them. They have risen 118% since 30 March.
In comparison AAZ have risen 55%.

[fozzie] 15/5/2020 07:55

Of course tea for breakfast, first coffee is mid morning, where were you dragged up MF?

[mad foetus] 15/5/2020 07:54

I think DDDD has the potential to match AVCT, but damn I wish I still had the latter.

[ntv] 15/5/2020 07:51

well done to those in AVCT
I have got to learn to take a punt at a few different types of stock from my norm

[mad foetus] 15/5/2020 07:46

Tea for breakfast. Wtaf?

[hubs] 15/5/2020 07:42

A few years ago the boss of Yorkshire Tea told his concerned kids over the breakfast table, that his company would plant a million trees to help combat climate change etc.
I think they have now planted over 5 million. Slurp and down it goes, lovely stuff.
Sweetened by that AVCT RNS!

[mr roper] 15/5/2020 07:41

Having my Yorkshire tea now.

[gold finger 1] 15/5/2020 07:31

Gutterhead

thanks for that link

[bumpa33] 15/5/2020 07:26

Very nice from AVCT, might have a look at that first thing.

[mad foetus] 15/5/2020 07:25

I sold all my AVCT...only got myself to blame. Bought DDDD and ACP instead...arghhh!

[wanobi] 15/5/2020 07:22

proper OIL at 32, Gold at 1735,,,, all shaping up chaps,,, fingers crossed, cheers Wan :-)

next book enroute :-)

famous last words again Wan!!!!!! LOL LOL

[ntv] 15/5/2020 07:22

Yorkshire tea is the best for a cuppa I'd say as well
Though I drink coffee a lot

[wanobi] 15/5/2020 07:16

AVCT - just had to post the content,,, GLA Cheers Wan :-)

15 May 2020

Avacta Group plc

("Avacta" or "the Group" or "the Company")

SARS-COV-2 Neutralising Affimers - Potential for a COVID-19 Therapy

Affimer(R) reagents discovered that block the virus' interaction with ACE2 which is key

to how the virus infects human cells

Avacta Group plc (AIM: AVCT), the developer of Affimer(R) biotherapeutics and reagents, is pleased to announce that several of the Affimer reagents recently generated for development of a point-of-care COVID-19 antigen saliva test have now also been shown to block the interaction between the virus' spike protein and ACE2, a receptor on human cells that is key to the virus infection pathway(1) .

Avacta has already successfully generated a large number of Affimer reagents that bind to the SARS-COV-2 virus' spike protein as part of its partnership with Cytiva (formerly GE Healthcare Life Sciences and now part of Danaher Corp). As previously announced, Avacta and Cytiva are working together to develop a rapid point-of-care COVID-19 antigen saliva test to be mass produced for large-scale population screening and for self-testing by consumers.

Further work at Avacta(2) has now shown that several of these Affimer reagents block the interaction between the virus' spike protein and a receptor found on human cells, called ACE2, to which the virus spike protein binds in order to infect cells. Affimer reagents that block the binding of the virus spike protein to ACE2 therefore have the potential to prevent infection and act as "neutralising" therapies.

Neutralising therapies could be given to those exposed to the virus (such as health and social-care workers) to prevent infection, as well as to patients already infected by the virus, to help treat and prevent disease progression.

Large pharmaceutical companies, such as AstraZeneca and GSK, are now starting programmes to develop neutralising antibodies in an attempt to block the SARS-COV-2 spike protein's interaction with ACE2. Avacta has now demonstrated that several Affimer reagents also perform this blocking function and the Company is now seeking a partner that has the resources available to develop a neutralising Affimer therapy as quickly as possible.

Dr Alastair Smith, Chief Executive Officer of Avacta Group, commented:

"This is a very exciting development in the COVID-19 programme. It only took four weeks to generate more than fifty Affimer reagents that bind the SARS-COV-2 virus spike protein and amongst those we now know that there are neutralising Affimers that block the interaction with a key human cell surface receptor, raising the potential for a therapy to prevent infection.

Recently GSK invested $250 million in Vir Biotechnology Inc(3) to develop potential antibody treatments for COVID-19 by selecting antibodies from recovered patients, and AstraZeneca also recently announced that it would start a programme to find new monoclonal antibodies that block the spike/ACE2 interaction(4) .

There is significant potential for a therapy that could help prevent infection and limit the progression of the disease, providing immediate benefit to patients. With a large and well-resourced partner, a neutralising Affimer therapy could potentially be developed more quickly than a vaccine and we believe that the likelihood of success would be high.

I look forward to updating the market further on this and on the development of a COVID-19 antigen rapid saliva test with Cytiva which continues apace."

[walter walcarpets] 15/5/2020 07:16

Good timing Brasso! Silver really breaking out now.